Company Overview
Pfizer is a global pharmaceutical company that develops and sells prescription medicines. Its business spans a broad portfolio of therapies, with revenue coming from the sale of branded drugs. The company operates at large scale, with an equity value of about USD 156.8 billion. The stock base is broad, with roughly 5.7 billion shares outstanding.
Analysis of recent data
FundamentalsIn its latest annual filing, reported in USD, Pfizer recorded revenue of about USD 1.8 billion and net income of roughly USD 7.8 billion. Over the same period, revenue grew 12.6% year over year, while trailing margins remained high on a gross basis at 75.81%, with a 15.43% operating margin and a 12.42% net profit margin.
From a balance-sheet angle, cash of about USD 1.1 billion sits against total debt of roughly USD 6.3 billion. The year also included USD 6.6 billion of depreciation and amortization and USD 2.6 billion of capital spending, showing how funding and non-cash charges interact with reported earnings.
Valuation
DCF / MultiplesAt USD 27.57, the stock price sits below the range implied by discounted cash flow outcomes, even under the weaker scenario. The current pricing also lines up with headline multiples of about 20.17x trailing earnings and 15.17x EV/EBITDA, alongside a price-to-sales ratio near 2.51.
Conclusion
TakeawayThe current price assumes a cautious view of balance-sheet capacity. That can work if cash generation holds up consistently. Debt staying manageable matters more than small margin moves. If cash stays thin versus obligations, the setup can unravel.